Mark Steven Cragg

Selinexor potentiates NK cell activation against multiple myeloma

INTRODUCTION: Selinexor is a first in class selective inhibitor of nuclear export (SINE) targeting Exportin-1 (XPO1) and approved for the treatment of multiple myeloma (MM). Selinexor has previously been shown to enhance natural killer (NK) cell activation against lymphoma cells...

Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo

Abstract Parkinson’s disease (PD), the most prevalent neurodegenerative movement disorder, is characterised by widespread alpha-synuclein (α-Syn) pathology in the brain and the progressive degeneration of nigrostriatal dopaminergic neurons. Experimental and clinicopathological da...